NEW YORK, April 18 - Orchid Bioscience said today it will fire 15 percent of its staff, or about 90 people, shift several operations, and shutter a number of facilities outright.

The company said it hopes the restructuring, which is expected to continue through the fall, will help it become profitable by the end of next year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.